Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

1245 pCMVb p300 Citations (6)

Originally described in: p300
Unpublished

Articles Citing 1245 pCMVb p300

Articles
Acetylation of a conserved lysine residue in the ATP binding pocket of p38 augments its kinase activity during hypertrophy of cardiomyocytes. Pillai VB, Sundaresan NR, Samant SA, Wolfgeher D, Trivedi CM, Gupta MP. Mol Cell Biol. 2011 Jun;31(11):2349-63. doi: 10.1128/MCB.01205-10. Epub 2011 Mar 28. PubMed
Mammalian two-hybrid assays for studies of interaction of p300 with transcription factors. Mendonca DB, Mendonca G, Cooper LF. Methods Mol Biol. 2013;977:323-38. doi: 10.1007/978-1-62703-284-1_26. PubMed
Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. Hu J, Lei Y, Wong WK, Liu S, Lee KC, He X, You W, Zhou R, Guo JT, Chen X, Peng X, Sun H, Huang H, Zhao H, Feng B. Nucleic Acids Res. 2014 Apr;42(7):4375-90. doi: 10.1093/nar/gku109. Epub 2014 Feb 5. PubMed
ZBRK1, a novel tumor suppressor, activates VHL gene transcription through formation of a complex with VHL and p300 in renal cancer. Chen K, Yu G, Gumireddy K, Li A, Yao W, Gao L, Chen S, Hao J, Wang J, Huang Q, Xu H, Ye Z. Oncotarget. 2015 Mar 30;6(9):6959-76. PubMed
Bioenergetic state regulates innate inflammatory responses through the transcriptional co-repressor CtBP. Shen Y, Kapfhamer D, Minnella AM, Kim JE, Won SJ, Chen Y, Huang Y, Low LH, Massa SM, Swanson RA. Nat Commun. 2017 Sep 22;8(1):624. doi: 10.1038/s41467-017-00707-0. PubMed
Combined HAT/EZH2 modulation leads to cancer-selective cell death. Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-Megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L. Oncotarget. 2018 May 22;9(39):25630-25646. doi: 10.18632/oncotarget.25428. eCollection 2018 May 22. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.